Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
Genelux Corporation (GNLX)
Company Research
Source: GlobeNewswire
WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2024 and provided general business updates. The Company initiated its second lung cancer trial, a US-based, Phase 2 trial (VIRO-25) treating patients with recurrent advanced or metastatic non-small cell lung cancer (NSCLC) with Olvi-Vec, followed by platinum-doublet chemotherapy + immune checkpoint inhibitor. Additionally, a Phase 1b/2 lung cancer trial is ongoing in recurrent small cell lung cancer (SCLC) in China which is co-sponsored with Newsoara BioPharma Co., Ltd. Both trials utilize Olvi-Vec delivered intravenously to treat patients who have previously failed platinum-based chemotherapy. The trials are designed based on earlier clinical results, including Olvi-Vec demonstrating (i) positive outcomes in patients with primary or metastatic lung cancer when delivered int
Show less
Read more
Impact Snapshot
Event Time:
GNLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GNLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GNLX alerts
High impacting Genelux Corporation news events
Weekly update
A roundup of the hottest topics
GNLX
News
- Genelux Co. (NASDAQ: GNLX) had its price target lowered by analysts at HC Wainwright from $32.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts [Yahoo! Finance]Yahoo! Finance
- Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates [Yahoo! Finance]Yahoo! Finance
- Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation ConferenceGlobeNewswire
- Genelux Co. (NASDAQ: GNLX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
GNLX
Earnings
- 11/14/24 - In-Line
GNLX
Sec Filings
- 11/14/24 - Form 10-Q
- 11/8/24 - Form 8-K
- 10/25/24 - Form SC
- GNLX's page on the SEC website